Matches in Wikidata for { <http://www.wikidata.org/entity/Q64621672> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q64621672 description "clinical trial" @default.
- Q64621672 description "ensayu clínicu" @default.
- Q64621672 description "klinisch onderzoek" @default.
- Q64621672 description "клінічне випробування" @default.
- Q64621672 name "Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients" @default.
- Q64621672 type Item @default.
- Q64621672 label "Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients" @default.
- Q64621672 prefLabel "Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients" @default.
- Q64621672 P1050 Q64621672-1B3C426B-4CAD-48B3-9C54-D90A71A1B806 @default.
- Q64621672 P1132 Q64621672-8E3076AD-2DC9-4710-AF71-79878B408AC7 @default.
- Q64621672 P1476 Q64621672-7B378648-7BE4-42C4-A812-62C866EC3097 @default.
- Q64621672 P17 Q64621672-025D04C9-2EA7-44BA-97BE-066FCD1E17C1 @default.
- Q64621672 P17 Q64621672-0740CB09-18D4-4ED8-B46F-B9B4B73F4E38 @default.
- Q64621672 P17 Q64621672-3AE6E15E-8193-4917-8046-A58C929B1707 @default.
- Q64621672 P17 Q64621672-41AAE44A-0D1D-4C3C-9C7F-B504BBA2E05C @default.
- Q64621672 P17 Q64621672-442787FA-7755-48FC-B6B6-264CBA515D71 @default.
- Q64621672 P17 Q64621672-479174D3-0477-4757-812B-D20AE01C4AA0 @default.
- Q64621672 P17 Q64621672-614F987C-DD1D-441F-8894-BD72E0B17F61 @default.
- Q64621672 P17 Q64621672-9773E519-F56A-41C7-B3FE-B1F5DD80CF4B @default.
- Q64621672 P17 Q64621672-A58CEFB3-169F-4CD0-8ED5-75AC5E5B8944 @default.
- Q64621672 P17 Q64621672-C060637A-1C39-40F8-9562-A4FB7FEBE3C2 @default.
- Q64621672 P1813 Q64621672-844DD88D-5987-4398-9848-87DC7D5ECCCF @default.
- Q64621672 P2899 Q64621672-667B0A07-FC5A-4D7B-A0D0-61231B740E8D @default.
- Q64621672 P3098 Q64621672-4723542D-41DB-4AE3-B182-3A18F26D29A4 @default.
- Q64621672 P31 Q64621672-81C7E805-5A52-42A2-8E0F-39E5EBD54780 @default.
- Q64621672 P4135 Q64621672-960E7ABC-4728-4E3E-A610-E1B18E2EE362 @default.
- Q64621672 P580 Q64621672-2D7874D8-0774-44D0-AE7E-472C76B460D9 @default.
- Q64621672 P582 Q64621672-22FA1559-BA06-4733-97C0-30B56137510E @default.
- Q64621672 P6099 Q64621672-2716AD1C-B2E3-47EB-A7CC-28494D73FE85 @default.
- Q64621672 P6099 Q64621672-5E80294B-796B-49E4-81B0-3266D4BF007A @default.
- Q64621672 P6153 Q64621672-F8C20EC3-4E39-4966-8652-DCCB804F087D @default.
- Q64621672 P8363 Q64621672-46B87C98-07F5-4AC0-9048-33DA1A566E63 @default.
- Q64621672 P859 Q64621672-A3CC8C39-A484-401D-8F75-00A767ABDCC6 @default.
- Q64621672 P1050 Q1433212 @default.
- Q64621672 P1132 "+251" @default.
- Q64621672 P1476 "A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Dose-finding, Pivotal, Phase 2b/3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous BYM338 at 52 Weeks on Physical Function, Muscle Strength, and Mobility and Additional Long Term Safety up to 2 Years in Patients With Sporadic Inclusion Body Myositis" @default.
- Q64621672 P17 Q142 @default.
- Q64621672 P17 Q145 @default.
- Q64621672 P17 Q17 @default.
- Q64621672 P17 Q30 @default.
- Q64621672 P17 Q31 @default.
- Q64621672 P17 Q35 @default.
- Q64621672 P17 Q38 @default.
- Q64621672 P17 Q39 @default.
- Q64621672 P17 Q408 @default.
- Q64621672 P17 Q55 @default.
- Q64621672 P1813 "RESILIENT" @default.
- Q64621672 P2899 "+36" @default.
- Q64621672 P3098 "NCT01925209" @default.
- Q64621672 P31 Q30612 @default.
- Q64621672 P4135 "+85" @default.
- Q64621672 P580 "2013-09-26T00:00:00Z" @default.
- Q64621672 P582 "2016-01-06T00:00:00Z" @default.
- Q64621672 P6099 Q42824440 @default.
- Q64621672 P6099 Q42824827 @default.
- Q64621672 P6153 Q507154 @default.
- Q64621672 P8363 Q78089383 @default.
- Q64621672 P859 Q507154 @default.